1. Home
  2. STAA vs HRMY Comparison

STAA vs HRMY Comparison

Compare STAA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

N/A

Current Price

$22.38

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$39.57

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STAA
HRMY
Founded
1982
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
2.4B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
STAA
HRMY
Price
$22.38
$39.57
Analyst Decision
Hold
Buy
Analyst Count
12
11
Target Price
$27.70
★ $47.36
AVG Volume (30 Days)
★ 847.4K
832.3K
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.97
EPS
0.26
★ 1.84
Revenue
$239,442,000.00
★ $868,453,000.00
Revenue This Year
$39.74
$18.74
Revenue Next Year
$7.76
$12.58
P/E Ratio
$85.58
★ $21.33
Revenue Growth
N/A
★ 21.51
52 Week Low
$15.59
$25.52
52 Week High
$35.87
$43.49

Technical Indicators

Market Signals
Indicator
STAA
HRMY
Relative Strength Index (RSI) 53.93 47.15
Support Level $21.72 $34.87
Resistance Level $24.31 $43.38
Average True Range (ATR) 0.89 1.25
MACD 0.26 -0.42
Stochastic Oscillator 92.33 26.15

Price Performance

Historical Comparison
STAA
HRMY

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: